Dualitas Therapeutics closed a $65 million Series A funding round to develop bispecific antibodies targeting two receptors on the same immune cell for enhanced immunomodulation in autoimmune and inflammatory diseases. Investors include Eli Lilly and Chugai Pharmaceutical. The Bay Area biotech focuses on leveraging proximity biology to create therapies that outperform traditional monoclonal antibodies.